This is probably the right decision given the circumstance. There is nothing to be gained by having the number of shares in the float increased and shareholders taking a 50% haircut. Back when this was originally set in motion it was expected to be from way higher levels with good progress being made on the business plan. NAZ up-listing etc. The subsequent PPS decline would have looked like a buying opportunity if things had gone smoothly.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links